Opportunity Information: Apply for RFA HL 09 011
Apply for RFA HL 09 011
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NHLBI Pediatric Translational Consortium Administrative Coordinating Center (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research.
- This funding opportunity was created on Dec 4, 2008 and posted on Dec 4, 2008.
- Applicants must submit their applications by Feb 6, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses For profit organizations other than small businesses Public and State controlled institutions of higher education Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) .
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NHLBI Pediatric Translational Consortium Administrative Coordinating Center (ACC) opportunity (RFA HL 09 011) is a cooperative agreement (U01) designed to fund a single organization to serve as the central administrative and operational hub for a new NHLBI pediatric cardiovascular translational research program. The ACC is meant to support and connect two NHLBI-supported consortia, the Cardiac Development Consortium and the Pediatric Cardiac Genomics Consortium, and to help them work in close coordination with the NHLBI Pediatric Heart Network. The larger goal is to speed the movement of discoveries from basic science into clinically relevant research in children with cardiovascular disease, while also ensuring that clinical needs and real-world questions help shape and prioritize basic research directions.
Under this U01 mechanism, the ACC is expected to do more than routine grant administration; it is structured as a cooperative agreement, meaning NHLBI will have substantial involvement in the project, and the ACC will be expected to coordinate activities across multiple participating groups in a highly collaborative environment. In practical terms, this coordinating center role typically includes organizing consortium governance and communications, supporting meetings and cross-consortium planning, harmonizing policies and procedures, facilitating collaboration between basic, genomic, and clinical investigators, and helping ensure that consortium efforts remain aligned with shared translational objectives. The ACC is also positioned to help create linkages between investigators generating developmental biology or genomics findings and clinicians who can guide how those findings might be tested, validated, or moved toward clinical research studies.
A distinctive feature of this announcement is that the ACC is not only funded to run coordination functions but is also responsible for administering additional shared resources referred to as cores. The total maximum award over the full six-year project period is $8.090 million in total costs, which includes up to $3.6 million for the ACC’s direct coordinating center activities and up to $4.490 million for the cores overseen by the ACC. For FY2009, NHLBI indicated an intention to commit approximately $400,000 in total costs. The project period is six years, and the first year is explicitly designated as a planning phase, which signals that NHLBI expects the awardee to use Year 1 to establish consortium-wide infrastructure, operating procedures, communication pathways, and any foundational planning needed to support full implementation in subsequent years. The maximum allowable direct costs are capped at $285,000 for the Year 1 planning phase and $455,000 per year for the remaining years.
Eligibility is broad and includes a range of academic, nonprofit, government, and private-sector organizations. Eligible applicants include public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, state governments, federal agencies, small businesses, and other for-profit organizations. The announcement also explicitly includes several institution types such as Historically Black Colleges and Universities, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, and Alaska Native and Native Hawaiian Serving Institutions. There is no cost-sharing or matching requirement.
Key logistical details include the posting date of December 4, 2008, and an application closing date of February 6, 2009, with the opportunity archived on March 9, 2009. The funding activity category is health, and it is associated with CFDA number 93.837 (Cardiovascular Diseases Research). Overall, the opportunity is aimed at building a well-coordinated, cross-disciplinary translational pipeline in pediatric cardiovascular disease by funding one central ACC that can align operations, support shared infrastructure, and actively connect basic discovery efforts with clinically informed research priorities.
FAQs: NHLBI Pediatric Translational Consortium Administrative Coordinating Center (ACC) (RFA HL 09 011)
What is this funding opportunity?
This opportunity (RFA HL 09 011) funds a single Pediatric Translational Consortium Administrative Coordinating Center (ACC) for a new NHLBI pediatric cardiovascular translational research program. The ACC serves as the central administrative and operational hub that supports coordination, planning, and day-to-day cross-consortium functioning.
What does ACC stand for, and what is the ACC expected to do?
ACC stands for Administrative Coordinating Center. The ACC is expected to function as more than a routine administrative office. It is designed to organize and support consortium governance and communications, support meetings and cross-consortium planning, harmonize policies and procedures, facilitate collaboration among participating investigators and groups, and help keep all efforts aligned with shared translational objectives in pediatric cardiovascular disease.
How many ACC awards will be made under this announcement?
The announcement is designed to fund a single organization to serve as the ACC, meaning one central coordinating center award is anticipated.
What funding mechanism is used?
The mechanism is a cooperative agreement (U01). This structure indicates substantial involvement by NHLBI in the project and emphasizes a collaborative, coordinated approach across multiple participating groups.
What does it mean that this is a cooperative agreement with substantial NHLBI involvement?
Because the award uses a U01 cooperative agreement mechanism, NHLBI is expected to have substantial involvement in the project. The ACC will be expected to operate in a highly collaborative environment and coordinate activities across multiple participating groups rather than working independently as in a standard grant model.
Which groups or consortia is the ACC intended to support and connect?
The ACC is meant to support and connect two NHLBI-supported consortia: the Cardiac Development Consortium and the Pediatric Cardiac Genomics Consortium. It is also expected to help these consortia work in close coordination with the NHLBI Pediatric Heart Network.
What is the overall goal of the ACC and the larger program?
The larger goal is to accelerate the movement of discoveries from basic science into clinically relevant research for children with cardiovascular disease, while also ensuring that clinical needs and real-world questions help shape and prioritize basic research directions.
What kinds of coordinating activities are typically included in the ACC role?
Based on the description provided, coordinating center responsibilities typically include organizing consortium governance and communications, supporting meetings and cross-consortium planning, harmonizing policies and procedures, facilitating collaboration between basic, genomic, and clinical investigators, and ensuring the program remains aligned with shared translational objectives.
How does the ACC help link basic discovery research with clinical research needs?
The ACC is positioned to create linkages between investigators generating developmental biology or genomics findings and clinicians who can guide how those findings might be tested, validated, or moved toward clinical research studies. It also supports a feedback loop where clinical needs help inform basic research priorities.
What is distinctive about this ACC opportunity compared with a typical coordinating center award?
A distinctive feature is that the ACC is not only funded to run coordination functions but is also responsible for administering additional shared resources referred to as cores. In other words, the ACC manages both coordination activities and the oversight/administration of shared core resources supported under the award.
What is the total maximum award amount and project length?
The total maximum award over the full six-year project period is $8.090 million in total costs.
How is the maximum total funding broken down between ACC activities and cores?
Of the $8.090 million maximum total costs over six years, up to $3.6 million is for the ACC's direct coordinating center activities and up to $4.490 million is for the cores overseen by the ACC.
What is NHLBI's stated funding intention for FY2009?
For FY2009, NHLBI indicated an intention to commit approximately $400,000 in total costs.
How long is the project period, and is there a dedicated planning phase?
The project period is six years. The first year is explicitly designated as a planning phase, signaling that Year 1 should be used to establish consortium-wide infrastructure, operating procedures, communication pathways, and foundational planning needed to support full implementation in later years.
What are the maximum allowable direct cost caps for Year 1 and later years?
Maximum allowable direct costs are capped at $285,000 for the Year 1 planning phase and $455,000 per year for the remaining years.
Is cost sharing or matching required?
No. The opportunity states there is no cost-sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, state governments, federal agencies, small businesses, and other for-profit organizations.
Are specific institution types explicitly included as eligible?
Yes. The announcement explicitly includes Historically Black Colleges and Universities, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, and Alaska Native and Native Hawaiian Serving Institutions.
What is the funding activity category and CFDA number?
The funding activity category is health. The opportunity is associated with CFDA number 93.837 (Cardiovascular Diseases Research).
What are the key dates listed for this opportunity?
The posting date is December 4, 2008. The application closing date is February 6, 2009. The opportunity was archived on March 9, 2009.
What does it mean that the opportunity is archived?
The listing indicates it was archived on March 9, 2009, which typically signals the public posting is no longer active for new submissions under that specific announcement as listed.
What research area or disease focus does this ACC support?
The focus is pediatric cardiovascular disease, with an emphasis on translational research that connects basic science (including developmental biology and genomics) to clinically relevant research in children.
How does this opportunity support cross-disciplinary collaboration?
It is designed to support collaboration across basic, genomic, and clinical investigators by centralizing governance, communications, planning, and policy/procedure harmonization, and by actively connecting discovery efforts with clinically informed translational priorities.
Browse more opportunities from the same category: Health
Next opportunity: Cardiac Translational Research Implementation Program (C TRIP) (P20)
Previous opportunity: NHLBI Pediatric Cardiac Genomics Consortium (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 09 011
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 09 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cardiac Translational Research Implementation Program (C TRIP) (P20) Apply for RFA HL 10 001 Funding Number: RFA HL 10 001 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Patient Reported Outcomes Measurement Information System (PROMIS) Network Center (U54) Apply for RFA RM 08 022 Funding Number: RFA RM 08 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Reported Outcomes Measurement Information System (PROMIS) Research Sites (U01) Apply for RFA RM 08 023 Funding Number: RFA RM 08 023 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Reported Outcomes Measurement Information System (PROMIS) Technology Center (U54) Apply for RFA RM 08 024 Funding Number: RFA RM 08 024 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Reported Outcomes Measurement Information System (PROMIS) Statistical Center (U54) Apply for RFA RM 08 025 Funding Number: RFA RM 08 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Small Grant Program For New Investigators (R03) Apply for PAR 09 031 Funding Number: PAR 09 031 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Malaria Communities Program FY09 RFA Apply for M OAA GH 09 252 Funding Number: M OAA GH 09 252 Agency: Agency for International Development Category: Health Funding Amount: $1,500,000 |
| Influenza and Other Emerging Infectious Diseases in Vietnam (U01) Apply for RFA IP 09 002 Funding Number: RFA IP 09 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Research and Public Health Practice on Influenza and other respiratory infectious diseases in the Middle East, Southeast Asia, and South American regions Apply for RFA IP 09 004 Funding Number: RFA IP 09 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,000,000 |
| Academic Research Enhancement Award (R15) Apply for PA 06 042 Funding Number: PA 06 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Patient Oriented Research Grant (R21) Apply for PA 06 086 Funding Number: PA 06 086 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIDCR Small Research Grants for Data Analysis and Statistical Methodology (R03) Apply for PAR 06 211 Funding Number: PAR 06 211 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Retirement Economics (R03) Apply for PA 06 235 Funding Number: PA 06 235 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Retirement Economics (R21) Apply for PA 06 236 Funding Number: PA 06 236 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Ancillary Studies to the AD Neuroimaging Initiative (R03) Apply for PA 06 240 Funding Number: PA 06 240 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Ancillary Studies to the Ad Neuroimaging Initiative (R21) Apply for PA 06 241 Funding Number: PA 06 241 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Aging Musculoskeletal and Skin Extracellular Matrix (R21) Apply for PA 06 242 Funding Number: PA 06 242 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| From Intervention Development to Services Exploratory Research Grants (R34) Apply for PAR 06 248 Funding Number: PAR 06 248 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Rapid Assessment Post Impact of Disaster (R03) Apply for PAR 06 252 Funding Number: PAR 06 252 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Rapid Assessment Post Impact of Disaster (R21) Apply for PAR 06 253 Funding Number: PAR 06 253 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 09 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.